Gender influence on selection and outcome of deep brain stimulation for Parkinson's disease.

Chandran S, Krishnan S, Rao RM, Sarma SG, Sarma PS, Kishore A.

Ann Indian Acad Neurol. 2014 Jan;17(1):66-70. doi: 10.4103/0972-2327.128557.

Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.

Mestre TA, Espay AJ, Marras C, Eckman MH, Pollak P, Lang AE.

Mov Disord. 2014 Dec;29(14):1751-6. doi: 10.1002/mds.26024. Review.

The incidence of Parkinson's disease in the North-East of England.

Duncan GW, Khoo TK, Coleman SY, Brayne C, Yarnall AJ, O'Brien JT, Barker RA, Burn DJ.

Age Ageing. 2014 Mar;43(2):257-63. doi: 10.1093/ageing/aft091.

Grey matter changes in cognitively impaired Parkinson's disease patients.

Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A.

PLoS One. 2014 Jan 21;9(1):e85595. doi: 10.1371/journal.pone.0085595.

Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging.

Teune LK, Renken RJ, de Jong BM, Willemsen AT, van Osch MJ, Roerdink JB, Dierckx RA, Leenders KL.

Neuroimage Clin. 2014 Jul 3;5:240-4. doi: 10.1016/j.nicl.2014.06.007.

The association between ambient exposure to organophosphates and Parkinson's disease risk.

Wang A, Cockburn M, Ly TT, Bronstein JM, Ritz B.

Occup Environ Med. 2014 Apr;71(4):275-81. doi: 10.1136/oemed-2013-101394.

[Modern ideas about pain syndrome in Parkinson's disease].

litvinenko IV, Bobkov AV.

Voen Med Zh. 2014 Oct;335(10):30-3. Review. Russian.

Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease.

Wu XL, Wang P, Liu YH, Xue YX.

J Mol Neurosci. 2014 May;53(1):1-9. doi: 10.1007/s12031-013-0175-5.

The future of cell therapies and brain repair: Parkinson's disease leads the way.

Petit GH, Olsson TT, Brundin P.

Neuropathol Appl Neurobiol. 2014 Feb;40(1):60-70. doi: 10.1111/nan.12110. Review.

Functional brain networks and cognitive deficits in Parkinson's disease.

Baggio HC, Sala-Llonch R, Segura B, Marti MJ, Valldeoriola F, Compta Y, Tolosa E, Junqué C.

Hum Brain Mapp. 2014 Sep;35(9):4620-34. doi: 10.1002/hbm.22499.

Motor, psychiatric and fatigue features associated with nutritional status and its effects on quality of life in Parkinson's disease patients.

Fereshtehnejad SM, Ghazi L, Shafieesabet M, Shahidi GA, Delbari A, Lökk J.

PLoS One. 2014 Mar 7;9(3):e91153. doi: 10.1371/journal.pone.0091153.

Tetranectin knockout mice develop features of Parkinson disease.

Wang ES, Zhang XP, Yao HB, Wang G, Chen SW, Gao WW, Yao HJ, Sun YR, Xi CH, Ji YD.

Cell Physiol Biochem. 2014;34(2):277-87. doi: 10.1159/000362998.

Triggering receptor expressed on myeloid cells 2 variants are rare in Parkinson's disease in a Han Chinese cohort.

Feng SJ, Nie K, Gan R, Huang J, Zhang YW, Wang LM, Zhao JH, Tang HM, Gao L, Zhu RM, Duan ZP, Zhang YH, Wang LJ.

Neurobiol Aging. 2014 Jul;35(7):1780.e11-2. doi: 10.1016/j.neurobiolaging.2014.01.142.

Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson's disease in Swedish population.

Yamada-Fowler N, Fredrikson M, Söderkvist P.

PLoS One. 2014 Jun 10;9(6):e99294. doi: 10.1371/journal.pone.0099294.

Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity.

Kahan J, Urner M, Moran R, Flandin G, Marreiros A, Mancini L, White M, Thornton J, Yousry T, Zrinzo L, Hariz M, Limousin P, Friston K, Foltynie T.

Brain. 2014 Apr;137(Pt 4):1130-44. doi: 10.1093/brain/awu027.